BridgeBio Pharma
BBIO
475 hedge funds and large institutions have $14.4B invested in BridgeBio Pharma in 2026 Q2 according to their latest regulatory filings, with 86 funds opening new positions, 173 increasing their positions, 168 reducing their positions, and 69 closing their positions.
451% more call options, than puts
Call options by funds: $849M | Put options by funds: $154M
25% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 69
3% more funds holding
Funds holding: 462 → 475 (+13)
3% more repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 168
0% less capital invested
Capital invested by funds: $14.4B → $14.4B (-$7.8M)
1.3% less ownership
Funds ownership: 100.16% → 98.87% (-1.3%)
31% less funds holding in top 10
Funds holding in top 10: 16 → 11 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$198M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$116M |
| 3 |
Two Sigma Investments
New York
|
+$112M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$107M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$96.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$275M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$145M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$133M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$133M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$105M |
BBIO Hedge Fund Activity: Q2 2026 in Review
475 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2026, worth a combined $14.4B — down 0.05% from $14.4B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new BBIO positions and 69 closed out — a net gain of 17 holders — while 173 added to existing stakes and 168 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $198M. The largest seller was BlackRock, cutting an estimated $275M.
- 475 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2026, up from 462 in Q1 2026.
- Funds reported $14.4B of BridgeBio Pharma stock for Q2 2026, down 0.05% quarter-over-quarter.
- 86 funds opened new BridgeBio Pharma positions in Q2 2026 and 69 closed out, a net change of +17 holders.
- The largest BridgeBio Pharma buyer in Q2 2026 was Wellington Management Group, an estimated $198M added.
- The largest BridgeBio Pharma seller in Q2 2026 was BlackRock, an estimated $275M sold.
Based on aggregated 13F filings for Q2 2026.